Jump to Main Contents
先端医療開発センター

Home > Organization > Division of Translational Genomics(Kashiwa) > Publications

Publications

2021

  1. Kashima Y, Shibahara D, Suzuki A, Muto K, Kobayashi IS, Plotnick D, Udagawa H, Izumi H, Shibata Y, Tanaka K, Fujii M, Ohashi A, Seki M, Goto K, Tuchihara K, Suzuki Y, and Kobayashi SS. Single-cell analyses reveal diverse mechanisms of resistance to EGFR tyrosine kinase inhibitors in lung cancer. Cancer Res. 2021 July 9. Epub 2021年07月12日. doi: 10.1158/0008-5472.CAN-20-2811. Cited in: Pubmed; PMID: 34247147
  2. Ishioka K, Yasuda H, Hamamoto J, Terai H, Emoto K, Kim TJ, Hirose S, Kamatani T, Mimaki S, Arai D, Ohgino K, Tani T, Masuzawa K, Manabe T, Shinozaki T, Mitsuishi A, Ebisudani T, Fukushima T, Ozaki M, Ikemura S, Kawada I, Naoki K, Nakamura M, Ohtsuka T, Asamura H, Tsuchihara K, Hayashi Y, Hegab AE, Kobayashi SS, Kohno T, Watanabe H, Ornitz DM, Betsuyaku T, Soejima K, Fukunaga K. Upregulation of fibroblast growth factor 9 in lung adenocarcinoma transdifferentiation to small cell lung cancer. Cancer Res. 2021 Jun 3. Epub 2021年06月05日. doi:10.1158/0008-5472.CAN-20-4048. Cited in: Pubmed; PMID 34083250.
  3. Iwai K, Nambu T, Kashima Y, Yu J, Eng K, Miyamoto K, Kakoi K, Gotou M, Takeuchi T, Kogame A, Sappal J, Murai S, Haeno H, Kageyama SI, Kurasawa O, Niu H, Kannan K, Ohashi A. A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery. Sci Adv. 2021 May;7(21). Epub 2021年05月23日. doi:10.1126/sciadv.abf0197. Cited in: Pubmed; PMID 34020950.
  4. Kashima Y, Togashi Y, Fukuoka S, Kamada T, Irie T, Suzuki A, Nakamura Y, Shitara K, Minamide T, Yoshida T, Taoka N, Kawase T, Wada T, Inaki K, Chihara M, Ebisuno Y, Tsukamoto S, Fujii R, Ohashi A, Suzuki Y, Tsuchihara K, Nishikawa H, Doi T. Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens. Sci Rep. 2021 Jan 11;11(1):341. Epub 2021年01月13日. doi:10.1038/s41598-020-79385-w. Cited in: Pubmed; PMID 33431933.
  5. Sehgal K, Rangachari D, VanderLaan PA, Kobayashi SS, Costa DB. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. Oncologist. 2021 Apr;26(4):281-287. Epub 2020年09月25日. doi:10.1002/onco.13537. Cited in: Pubmed; PMID 32969527.
  6. Trinh BQ, Ummarino S, Zhang Y, Ebralidze AK, Bassal MA, Nguyen TM, Heller G, Coffey R, Tenen DE, van der Kouwe E, Fabiani E, Gurnari C, Wu CS, Espinosa Angarica V, Yang H, Chen S, Zhang H, Thurm AR, Marchi F, Levantini E, Staber PB, Zhang P, Voso MT, Pandolfi PP, Kobayashi SS, Chai L, Di Ruscio A, Tenen DG. Myeloid lncRNA LOUP Mediates Opposing Regulatory Effects of RUNX1 and RUNX1-ETO in t(8;21) AML. Blood. 2021 May 10. Epub 2021年05月11日. doi:10.1182/blood.2020007920. Cited in: Pubmed; PMID 33971010.
  7. Vasconcelos P, Kobayashi IS, Kobayashi SS, Costa DB. Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations. JTO Clin Res Rep. 2021 Mar;2(3). Epub 2021年03月18日. doi:10.1016/j.jtocrr.2020.100105. Cited in: Pubmed; PMID 33728415.
  8. Watanabe S, Goto Y, Yasuda H, Kohno T, Motoi N, Ohe Y, Nishikawa H, Kobayashi SS, Kuwano K, Togashi Y. HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs. Thorac Cancer. 2021 Mar;12(5):631-642. Epub 2021年01月21日. doi:10.1111月17日59-7714.13839. Cited in: Pubmed; PMID 33471376.

2020

  1. Fujimoto Y, Morita TY, Ohashi A, Haeno H, Hakozaki Y, Fujii M, Kashima Y, Kobayashi SS, Mukohara T. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells. Sci Rep. 2020 Dec 10;10(1):21762. Epub 2020年12月12日. doi:10.1038/s41598-020-78646-y. Cited in: Pubmed; PMID 33303839.
  1. Jorge SE, Lucena-Araujo AR, Yasuda H, Piotrowska Z, Oxnard GR, Rangachari D, Huberman MS, Sequist LV, Kobayashi SS, Costa DB. Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clin Cancer Res. 2020 May 1;26(9):2277. Epub 2020年05月03日. doi:10.1158/1078-0432.CCR-20-0939. Cited in: Pubmed; PMID 32358026.
  1. Kurosawa O, Miyazaki T, Homma M, Oguro Y, Imada T, Uchiyama N, Iwai K, Yamamoto Y, Ohori M, Hara H, Sugimoto H, Iwata K, Skene R, Hoffman I, Ohashi A, Nomura T, Cho N. Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-d]pyrimidinone-Based Cdc7 Inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Antitumor Agent. J Med Chem. 2020 Feb 13;63(3):1084-1104. Epub 2020年01月03日. doi:10.1021/acs.jmedchem.9b01427. Cited in: Pubmed; PMID 31895562.
  1. Piper-Vallillo AJ, Halbert BT, Rangachari D, Kobayashi SS, Costa DB. Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer. JTO Clin Res Rep. 2020 Nov 1;1(4):100071. Epub 2020年11月24日. doi:10.1016/j.jtocrr.2020.100071. Cited in: Pubmed; PMID 33225315.
  1. Sakamoto Y, Xu L, Seki M, Yokoyama TT, Kasahara M, Kashima Y, Ohashi A, Shimada Y, Motoi N, Tsuchihara K, Kobayashi SS, Kohno T, Shiraishi Y, Suzuki A, Suzuki Y. Long-read sequencing for non-small-cell lung cancer genomes. Genome Res. 2020 Sep;30(9):1243-1257. Epub 2020年09月06日. doi:10.1101/gr.261941.120. Cited in: Pubmed; PMID 32887687.
  1. Takei H, Fukuda H, Pan G, Yamazaki H, Matsumoto T, Kazuma Y, Fujii M, Nakayama S, Kobayashi IS, Shindo K, Yamashita R, Shirakawa K, Takaori-Kondo A, Kobayashi SS. Alternative splicing of APOBEC3D generates functional diversity and its role as a DNA mutator. Int J Hematol. 2020 Sep;112(3):395-408. Epub 2020年06月14日. doi:10.1007/s12185-020-02904-y. Cited in: Pubmed; PMID 32533515.
  1. Vasconcelos P, Gergis C, Viray H, Varkaris A, Fujii M, Rangachari D, VanderLaan PA, Kobayashi IS, Kobayashi SS, Costa DB. EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors. JTO Clin Res Rep. 2020 Sep;1(3). Epub 2021年06月10日. doi:10.1016/j.jtocrr.2020.100051. Cited in: Pubmed; PMID 34104899.

2019

  1. Udagawa H, Hasako S, Ohashi A, Fujioka R, Hakozaki Y, Shibuya M, et al. TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically-relevant EGFR mutations. Mol Cancer Res. 2019. Epub 2019年08月31日. doi: 10.1158/1541-7786.MCR-19-0419. PubMed PMID: 31467113.
  2. Takenaka T, Nakai S, Katayama M, Hirano M, Ueno N, Noguchi K, et al. Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells. International journal of pharmaceutics. 2019;572:118762. doi: 10.1016/j.ijpharm.2019.118762. PubMed PMID: 31610280; PubMed Central PMCID: 6899172.
  3. Takei H, Kobayashi SS. Targeting transcription factors in acute myeloid leukemia. Int J Hematol. 2019;109(1):28-34. Epub 2018年06月30日. doi: 10.1007/s12185-018-2488-1. PubMed PMID: 29956082.
  4. Sehgal K, Peters MLB, VanderLaan PA, Rangachari D, Kobayashi SS, Costa DB. Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer. J Thorac Oncol. 2019;14(1):e1-e3. Epub 2018年07月10日. doi: 10.1016/j.jtho.2018.06.020. PubMed PMID: 29981924; PubMed Central PMCID: PMC6322846.
  5. Rangachari D, To C, Shpilsky JE, VanderLaan PA, Kobayashi SS, Mushajiang M, et al. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. J Thorac Oncol. 2019. Epub 2019年08月05日. doi: 10.1016/j.jtho.2019.07.016. PubMed PMID: 31377341.
  6. Radhakrishnan S, Syed R, Takei H, Kobayashi IS, Nakamura E, Sultana F, et al. Styryl quinazolinones and its ethynyl derivatives induce myeloid differentiation. Bioorg Med Chem Lett. 2019;29(16):2286-9. Epub 2019年07月07日. doi: 10.1016/j.bmcl.2019.06.024. PubMed PMID: 31278031.
  7. Kashima Y, Suzuki A, Suzuki Y. An Informative Approach to Single-Cell Sequencing Analysis. Adv Exp Med Biol. 2019;1129:81-96. Epub 2019年04月11日. doi: 10.1007/978-981-13-6037-4_6. PubMed PMID: 30968362.
  8. Iwai K, Nambu T, Dairiki R, Ohori M, Yu J, Burke K, et al. Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor. Sci Adv. 2019;5(5):eaav3660. Epub 2019年05月28日. doi: 10.1126/sciadv.aav3660. PubMed PMID: 31131319; PubMed Central PMCID: PMC6531005.
  9. Ikemura S, Yasuda H, Matsumoto S, Kamada M, Hamamoto J, Masuzawa K, et al. Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. Proc Natl Acad Sci U S A. 2019;116(20):10025-30. Epub 2019年05月03日. doi: 10.1073/pnas.1819430116. PubMed PMID: 31043566; PubMed Central PMCID: PMC6525482.

2018

  1. VanderLaan PA, Rangachari D, Majid A, Parikh MS, Gangadharan SP, Kent MS, et al. Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer. 2018;116:90-5. Epub 2018年02月08日. doi: 10.1016/j.lungcan.2018.01.002. PubMed PMID: 29413057; PubMed Central PMCID: PMC5806129.
  2. Sridhar R, Takei H, Syed R, Kobayashi IS, Hui LB, Kamal A, et al. Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBPalpha. Molecules. 2018;23(8). Epub 2018年08月08日. doi: 10.3390/molecules23081938. PubMed PMID: 30081475; PubMed Central PMCID: PMC6222906.
  3. Miyai T, Takano J, Endo TA, Kawakami E, Agata Y, Motomura Y, et al. Three-step transcriptional priming that drives the commitment of multipotent progenitors toward B cells. Genes Dev. 2018;32(2):112-26. Epub 2018年02月15日. doi: 10.1101/gad.309575.117. PubMed PMID: 29440259; PubMed Central PMCID: PMC5830925.
  4. Kobayashi SS, Takei H. [Transcription factor-based therapies for acute myeloid leukemia]. Rinsho Ketsueki. 2018;59(7):922-31. Epub 2018年08月07日. doi: 10.11406/rinketsu.59.922. PubMed PMID: 30078804.
  5. Kashima Y, Suzuki A, Liu Y, Hosokawa M, Matsunaga H, Shirai M, et al. Combinatory use of distinct single-cell RNA-seq analytical platforms reveals the heterogeneous transcriptome response. Sci Rep. 2018;8(1):3482. Epub 2018年02月24日. doi: 10.1038/s41598-018-21161-y. PubMed PMID: 29472726; PubMed Central PMCID: PMC5823859.
  6. Jorge SE, Lucena-Araujo AR, Yasuda H, Piotrowska Z, Oxnard GR, Rangachari D, et al. EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clin Cancer Res. 2018;24(24):6548-55. Epub 2018年08月30日. doi: 10.1158/1078-0432.CCR-18-1541. PubMed PMID: 30154228; PubMed Central PMCID: PMC6295229.
  7. Nakayama K., Szewczyk M., Sena CD., Wu H., Dong A., Zeng H., et al. TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma therapy. Oncotarget 9(26): 18480-18493. 2018. DOI: 10.18632/oncotarget.24883

2017

  1.  VanderLaan PA, Rangachari D, Mockus SM, Spotlow V, Reddi HV, Malcolm J, et al. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer. 2017;16時17分-21. doi: 10.1016/j.lungcan.2017.01.011. PubMed PMID: 28285689; PubMed Central PMCID: 5351777.
  2. Takenaka T, Katayama M, Sugiyama A, Hagiwara M, Fujii I, Takatani-Nakase T, et al. Gefitinib Enhances Mitochondrial Biological Functions in NSCLCs with EGFR Mutations at a High Cell Density. Anticancer research. 2017;37(9):4779-88. doi: 10.21873/anticanres.11884. PubMed PMID: 28870896.
  3. Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, et al. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 >/=50% Expression in Lung Adenocarcinoma. J Thorac Oncol. 2017;12(5):878-83. doi: 10.1016/j.jtho.2016.12.026. PubMed PMID: 28104537; PubMed Central PMCID: 5403565.
  4. Rangachari D, Le X, Shea M, Huberman MS, VanderLaan PA, Kobayashi SS, et al. Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. J Thorac Oncol. 2017. doi: 10.1016/j.jtho.2017.06.002. PubMed PMID: 28611010.
  5. Kon S, Ishibashi K, Katoh H, Kitamoto S, Shirai T, Tanaka S, et al. Cell competition with normal epithelial cells promotes apical extrusion of transformed cells through metabolic changes. Nat Cell Biol. 2017;19(5):530-41. Epub 2017年04月18日. doi: 10.1038/ncb3509. PubMed PMID: 28414314.
  6. Kadeer A, Maruyama T, Kajita M, Morita T, Sasaki A, Ohoka A, et al. Plectin is a novel regulator for apical extrusion of RasV12-transformed cells. Sci Rep. 2017;7時44分328. Epub 2017年03月11日. doi: 10.1038/srep44328. PubMed PMID: 28281696; PubMed Central PMCID: PMC5345014.
  7. Jinushi M, Morita T, Xu Z, Kinoshita I, Dosaka-Akita H, Yagita H, et al. Autophagy-dependent regulation of tumor metastasis by myeloid cells. PLoS One. 2017;12(7):e0179357. Epub 2017年07月08日. doi: 10.1371/journal.pone.0179357. PubMed PMID: 28686632; PubMed Central PMCID: PMC5501406.
  8. Jin J, Zhan P, Katoh M, Kobayashi SS, Phan K, Qian H, et al. Prognostic significance of beta-catenin expression in patients with non-small cell lung cancer: a meta-analysis. Translational lung cancer research. 2017;6(1):97-108. doi: 10.21037/tlcr.2017.02.07. PubMed PMID: 28331830; PubMed Central PMCID: 5344847.
  9. Gonzalez D, Luyten A, Bartholdy B, Zhou Q, Kardosova M, Ebralidze A, et al. ZNF143 is an important regulator of the myeloid transcription factor C/EBPalpha. The Journal of biological chemistry. 2017. doi: 10.1074/jbc.M117.811109. PubMed PMID: 28900037.
  10. Kurasawa O., Homma M., Oguro Y., Miyazaki T., Mori K., Uchiyama N., et al. 2-Aminomethylthieno[3,2-d]pyrimidin-4(3H)-ones bearing 3-methylpyrazole hinge binding moiety: Highly potent, selective, and time-dependent inhibitors of Cdc7 kinase. Bioorg Med Chem. 25(14):3658-3670. 2017
  11. Kurasawa O., Oguro Y., Miyazaki T., Homma M., Mori K., Iwai K., et al. Identification of a new class of potent Cdc7 inhibitors designed by putative pharmacophore model: Synthesis and biological evaluation of 2,3-dihydrothieno[3,2-d]pyrimidin-4(1H)-ones. Bioorg Med Chem. 25(7):2133-2147. 2017

2016

  1. Ohashi A, Ohori M, Iwai K. Motor activity of centromere-associated protein-E contributes to its localization at the center of the midbody to regulate cytokinetic abscission. Oncotarget. 2016;7(48):79964-80. Epub 2016年11月12日. doi: 10.18632/oncotarget.13206. PubMed PMID: 27835888; PubMed Central PMCID: PMC5346764.
  2. Lucena-Araujo AR, Moran JP, VanderLaan PA, Dias-Santagata D, Folch E, Majid A, et al. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naive ALK rearranged lung cancers. Lung Cancer. 2016;99:17-22. doi: 10.1016/j.lungcan.2016.06.006. PubMed PMID: 27565908; PubMed Central PMCID: 5002311.
  3. Kobayashi SS, Vali S, Kumar A, Singh N, Abbasi T, Sayeski PP. Identification of myeloproliferative neoplasm drug agents via predictive simulation modeling: assessing responsiveness with micro-environment derived cytokines. Oncotarget. 2016;7(24):35989-6001. doi: 10.18632/oncotarget.8540. PubMed PMID: 27056884; PubMed Central PMCID: 5094977.
  4. Goto K, Annan DA, Morita T, Li W, Muroyama R, Matsubara Y, et al. Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study. Sci Rep. 2016;6時38分407. Epub 2016年12月03日. doi: 10.1038/srep38407. PubMed PMID: 27910927; PubMed Central PMCID: PMC5133582 Y.T., and N.K. declare no competing interests.
  5. Costa DB, Jorge SE, Moran JP, Freed JA, Zerillo JA, Huberman MS, et al. Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas. J Thorac Oncol. 2016;11(6):918-23. doi: 10.1016/j.jtho.2016.02.016. PubMed PMID: 26964772; PubMed Central PMCID: 4877224.
  6. Hirayama T., Okaniwa M., Banno H, Kamei H., Ohashi A., Ohori M., et al. Design and Synthesis of Fused Bicyclic Inhibitors Targeting the L5 Loop Site of Centromere-Associated Protein E. Bio Med Chem Lett. 26(17): 4296-300. 2016. DOI:10.1016/j.bmcl.2016.07.038

2015

  1. Yamauchi H, Matsumaru T, Morita T, Ishikawa S, Maenaka K, Takigawa I, et al. The cell competition-based high-throughput screening identifies small compounds that promote the elimination of RasV12-transformed cells from epithelia. Sci Rep. 2015;5時15分336. Epub 2015年10月21日. doi: 10.1038/srep15336. PubMed PMID: 26480891; PubMed Central PMCID: PMC4612300.
  2. Radomska HS, Jernigan F, Nakayama S, Jorge SE, Sun L, Tenen DG, et al. A Cell-Based High-Throughput Screening for Inducers of Myeloid Differentiation. Journal of biomolecular screening. 2015;20(9):1150-9. Epub 2015年06月26日. doi: 10.1177/1087057115592220. PubMed PMID: 26109609; PubMed Central PMCID: PMC4575897.
  3. Ohashi A, Ohori M, Iwai K, Nambu T, Miyamoto M, Kawamoto T, et al. A Novel Time-Dependent CENP-E Inhibitor with Potent Antitumor Activity. PLoS One. 2015;10(12):e0144675. Epub 2015年12月10日. doi: 10.1371/journal.pone.0144675. PubMed PMID: 26649895; PubMed Central PMCID: PMC4674098.
  4. Ohashi A, Ohori M, Iwai K, Nakayama Y, Nambu T, Morishita D, et al. Aneuploidy generates proteotoxic stress and DNA damage concurrently with p53-mediated post-mitotic apoptosis in SAC-impaired cells. Nat Commun. 2015;6:7668. Epub 2015年07月07日. doi: 10.1038/ncomms8668. PubMed PMID: 26144554; PubMed Central PMCID: PMC4506520.
  5. Le X, Freed JA, VanderLaan PA, Huberman MS, Rangachari D, Jorge SE, et al. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. Clinical lung cancer. 2015;16(5):e105-9. doi: 10.1016/j.cllc.2015.03.002. PubMed PMID: 25922291; PubMed Central PMCID: 4418215.
  6. Komohara Y, Morita T, Annan DA, Horlad H, Ohnishi K, Yamada S, et al. The Coordinated Actions of TIM-3 on Cancer and Myeloid Cells in the Regulation of Tumorigenicity and Clinical Prognosis in Clear Cell Renal Cell Carcinomas. Cancer Immunol Res. 2015;3(9):999-1007. Epub 2015年03月19日. doi: 10.1158/2326-6066.CIR-14-0156. PubMed PMID: 25783986.
  7. Jorge SE, Schulman S, Freed JA, VanderLaan PA, Rangachari D, Kobayashi SS, et al. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer. 2015;90(3):369-74. doi: 10.1016/j.lungcan.2015.10.028. PubMed PMID: 26791794; PubMed Central PMCID: 4724060.
  8. Hirano T, Yasuda H, Tani T, Hamamoto J, Oashi A, Ishioka K, et al. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget. 2015;6(36):38789-803. doi: 10.18632/oncotarget.5887. PubMed PMID: 26515464; PubMed Central PMCID: 4770737.
  9. Costa DB, Kobayashi SS. Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. Translational lung cancer research. 2015;4(6):809-15. doi: 10.3978/j.issn.2218-6751.2015.05.05. PubMed PMID: 26798593; PubMed Central PMCID: 4700227.
  10. Cai Y, Hirata A, Nakayama S, VanderLaan PA, Levantini E, Yamamoto M, et al. CCAAT/enhancer binding protein beta is dispensable for development of lung adenocarcinoma. PLoS One. 2015;10(3):e0120647. doi: 10.1371/journal.pone.0120647. PubMed PMID: 25767874; PubMed Central PMCID: 4358974.
  11. Nakayama Y. and Ohashi A. Expression data of HeLa cells treated with CENP-E siRNA or Eg5 siRNA in the presence of BubR1 siRNA (Data in Brief). Genomics Data. 6 44-45. 2015. DOI:10.1016/j.gdata.2015.08.002.
  12. Hirayama T., Okaniwa M., Banno H., Kakei H., Ohashi A., Iwai K., et al. Synthetic Studies on Centromere-Associated Protein-E (CENP-E) Inhibitors: 2. Application of Electrostatic Potential Map (EPM) and Structure-Based Modeling to Imidazo[1,2-a]pyridine Derivatives as Anti-Tumor Agents. J. Med. Chem. 58 (20):8036–8053. 2015

1998-2014

  1. Nakayama S, Sng N, Carretero J, Welner R, Hayashi Y, Yamamoto M, Tan AJ, Yamaguchi N, Yasuda H, Li D, Soejima K, Soo RA, Costa DB, Wong KK, Kobayashi SS. beta-catenin contributes to lung tumor development induced by EGFR mutations. Cancer research. 2014;74(20):5891-902. doi: 10.1158/0008-5472.CAN-14-0184. PubMed PMID: 25164010; PMCID: 4199914.
  2. Jorge SE, Kobayashi SS, Costa DB. Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. 2014;0時0分. PubMed PMID: 25211582.
  3. de Figueiredo-Pontes LL, Wong DW, Tin VP, Chung LP, Yasuda H, Yamaguchi N, Nakayama S, Janne PA, Wong MP, Kobayashi SS, Costa DB. Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer. J Thorac Oncol. 2014;9(2):248-53. doi: 10.1097/JTO.0000000000000050. PubMed PMID: 24419423; PMCID: 4096850.
  4. Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Science translational medicine. 2013;5(216):216ra177. doi: 10.1126/scitranslmed.3007205. PubMed PMID: 24353160; PMCID: 3954775.
  5. Tsuchiya Y, Taniguchi H, Ito Y, Morita T, Karim MR, Ohtake N, Fukagai K, Ito T, Okamuro S, Iemura S, Natsume T, Nishida E, Kobayashi A. The casein kinase 2-nrf1 axis controls the clearance of ubiquitinated proteins by regulating proteasome gene expression. Mol Cell Biol. 2013;33(17):3461-72. Epub 2013年07月03日. doi: 10.1128/MCB.01271-12. PubMed PMID: 23816881; PMCID: PMC3753846.
  6. Mondal G, Ohashi A, Yang L, Rowley M, Couch FJ. Tex14, a Plk1-regulated protein, is required for kinetochore-microtubule attachment and regulation of the spindle assembly checkpoint. Mol Cell. 2012;45(5):680-95. Epub 2012年03月13日. doi: 10.1016/j.molcel.2012.01.013. PubMed PMID: 22405274; PMCID: PMC3302152.
  7. Basseres DS, D'Alo F, Yeap BY, Lowenberg EC, Gonzalez DA, Yasuda H, Dayaram T, Kocher ON, Godleski JJ, Richards WG, Meyerson M, Kobayashi S, Tenen DG, Halmos B, Costa DB. Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. Lung Cancer. 2012;77(1):31-7. doi: 10.1016/j.lungcan.2012.01.011. PubMed PMID: 22341411; PMCID: 3368092.
  8. Tsuchiya Y, Morita T, Kim M, Iemura S, Natsume T, Yamamoto M, Kobayashi A. Dual regulation of the transcriptional activity of Nrf1 by beta-TrCP- and Hrd1-dependent degradation mechanisms. Mol Cell Biol. 2011;31(22):4500-12. Epub 2011年09月14日. doi: 10.1128/MCB.05663-11. PubMed PMID: 21911472; PMCID: PMC3209242.
  9. Rowley M, Ohashi A, Mondal G, Mills L, Yang L, Zhang L, Sundsbak R, Shapiro V, Muders MH, Smyrk T, Couch FJ. Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology. 2011;140(4):1303-13 e1-3. Epub 2011年01月05日. doi: 10.1053/j.gastro.2010.12.039. PubMed PMID: 21199651; PMCID: PMC3066280.
  10. Kobayashi A, Tsukide T, Miyasaka T, Morita T, Mizoroki T, Saito Y, Ihara Y, Takashima A, Noguchi N, Fukamizu A, Hirotsu Y, Ohtsuji M, Katsuoka F, Yamamoto M. Central nervous system-specific deletion of transcription factor Nrf1 causes progressive motor neuronal dysfunction. Genes Cells. 2011;16(6):692-703. Epub 2011年05月11日. doi: 10.1111/j.1365-2443.2011.01522.x. PubMed PMID: 21554501.
  11. Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol. 2010;5(7):1048-53. doi: 10.1097/JTO.0b013e3181dd1386. PubMed PMID: 20512075; PMCID: 2893286.
  12. Will B, Siddiqi T, Jorda MA, Shimamura T, Luptakova K, Staber PB, Costa DB, Steidl U, Tenen DG, Kobayashi S. Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood. 2010;115(14):2901-9. doi: 10.1182/blood-2009-03-209544. PubMed PMID: 20160166; PMCID: 2854433.
  13. O'Brien KB, Alberich-Jorda M, Yadav N, Kocher O, Diruscio A, Ebralidze A, Levantini E, Sng NJ, Bhasin M, Caron T, Kim D, Steidl U, Huang G, Halmos B, Rodig SJ, Bedford MT, Tenen DG, Kobayashi S. CARM1 is required for proper control of proliferation and differentiation of pulmonary epithelial cells. Development. 2010;137(13):2147-56. doi: 10.1242/dev.037150. PubMed PMID: 20530543; PMCID: 2882134.
  14. Grant PM, Palmer S, Bendavid E, Talbot A, Slamowitz DC, Cain P, Kobayashi SS, Balamane M, Zolopa AR. Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2009;46(4):305-8. doi: 10.1016/j.jcv.2009.09.025. PubMed PMID: 19819183; PMCID: 4467791.
  15. Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E, Borgman CL, Lowell AM, Minami Y, McNamara K, Perera SA, Zaghlul S, Thomas RK, Greulich H, Kobayashi S, Chirieac LR, Padera RF, Kubo S, Takahashi M, Tenen DG, Meyerson M, Wong KK, Shapiro GI. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer research. 2008;68(14):5827-38. doi: 10.1158/0008-5472.CAN-07-5428. PubMed PMID: 18632637; PMCID: 3272303.
  16. Costa DB, Schumer ST, Tenen DG, Kobayashi S. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(7):1182-4; author reply 4-6. doi: 10.1200/JCO.2007.14.9039. PubMed PMID: 18309959.
  17. Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Janne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 2008;14(21):7060-7. doi: 10.1158/1078-0432.CCR-08-1455. PubMed PMID: 18981003; PMCID: 2596582.
  18. Cha HC, Oak NR, Kang S, Tran TA, Kobayashi S, Chiang SH, Tenen DG, MacDougald OA. Phosphorylation of CCAAT/enhancer-binding protein alpha regulates GLUT4 expression and glucose transport in adipocytes. The Journal of biological chemistry. 2008;283(26):18002-11. doi: 10.1074/jbc.M800419200. PubMed PMID: 18408001; PMCID: 2440616.
  19. Yu Z, Boggon TJ, Kobayashi S, Jin C, Ma PC, Dowlati A, Kern JA, Tenen DG, Halmos B. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer research. 2007;67(21):10417-27. doi: 10.1158/0008-5472.CAN-07-1248. PubMed PMID: 17974985.
  20. Steidl U, Steidl C, Ebralidze A, Chapuy B, Han HJ, Will B, Rosenbauer F, Becker A, Wagner K, Koschmieder S, Kobayashi S, Costa DB, Schulz T, O'Brien KB, Verhaak RG, Delwel R, Haase D, Trumper L, Krauter J, Kohwi-Shigematsu T, Griesinger F, Tenen DG. A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. The Journal of clinical investigation. 2007;117(9):2611-20. doi: 10.1172/JCI30525. PubMed PMID: 17694175; PMCID: 1937499.
  21. Koschmieder S, D'Alo F, Radomska H, Schoneich C, Chang JS, Konopleva M, Kobayashi S, Levantini E, Suh N, Di Ruscio A, Voso MT, Watt JC, Santhanam R, Sargin B, Kantarjian H, Andreeff M, Sporn MB, Perrotti D, Berdel WE, Muller-Tidow C, Serve H, Tenen DG. CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood. 2007;110(10):3695-705. doi: 10.1182/blood-2006-11-058941. PubMed PMID: 17671235; PMCID: 2077317.
  22. Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer. 2007;58(1):95-103. doi: 10.1016/j.lungcan.2007.05.017. PubMed PMID: 17610986; PMCID: 2551312.
  23. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS medicine. 2007;4(10):1669-79; discussion 80. doi: 10.1371/journal.pmed.0040315. PubMed PMID: 17973572; PMCID: 2043012.
  24. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell. 2006;22(6):719-29. Epub 2006年06月24日. doi: 10.1016/j.molcel.2006.05.022. PubMed PMID: 16793542.
  25. Wagner K, Zhang P, Rosenbauer F, Drescher B, Kobayashi S, Radomska HS, Kutok JL, Gilliland DG, Krauter J, Tenen DG. Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. Proc Natl Acad Sci U S A. 2006;103(16):6338-43. doi: 10.1073/pnas.0508143103. PubMed PMID: 16606850; PMCID: 1458879.
  26. Kubo S, Levantini E, Kobayashi S, Kocher O, Halmos B, Tenen DG, Takahashi M. Three-dimensional magnetic resonance microscopy of pulmonary solitary tumors in transgenic mice. Magnetic resonance in medicine. 2006;56(3):698-703. doi: 10.1002/mrm.21006. PubMed PMID: 16902979.
  27. Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, Golub T, Meyerson M, Tenen DG, Shapiro GI, Halmos B. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer research. 2006;66(23):11389-98. doi: 10.1158/0008-5472.CAN-06-2318. PubMed PMID: 17145885.
  28. Wu K, Hinson SR, Ohashi A, Farrugia D, Wendt P, Tavtigian SV, Deffenbaugh A, Goldgar D, Couch FJ. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer research. 2005;65(2):417-26. Epub 2005年02月08日. PubMed PMID: 15695382.
  29. Ohashi A, Zdzienicka MZ, Chen J, Couch FJ. Fanconi anemia complementation group D2 (FANCD2) functions independently of BRCA2- and RAD51-associated homologous recombination in response to DNA damage. The Journal of biological chemistry. 2005;280(15):14877-83. Epub 2005年01月27日. doi: 10.1074/jbc.M414669200. PubMed PMID: 15671039.
  30. Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Janne PA. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. Journal of the National Cancer Institute. 2005;97(16):1185-94. doi: 10.1093/jnci/dji238. PubMed PMID: 16106023.
  31. Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG, Halmos B. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer research. 2005;65(16):7096-101. doi: 10.1158/0008-5472.CAN-05-1346. PubMed PMID: 16103058.
  32. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. The New England journal of medicine. 2005;352(8):786-92. doi: 10.1056/NEJMoa044238. PubMed PMID: 15728811.
  33. Kobayashi S, Yamashita K, Takeoka T, Ohtsuki T, Suzuki Y, Takahashi R, Yamamoto K, Kaufmann SH, Uchiyama T, Sasada M, Takahashi A. Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic leukemia. The Journal of biological chemistry. 2002;277(37):33968-77. doi: 10.1074/jbc.M203350200. PubMed PMID: 12121983.
  34. Yamashita K, Takahashi A, Kobayashi S, Hirata H, Mesner PW, Jr., Kaufmann SH, Yonehara S, Yamamoto K, Uchiyama T, Sasada M. Caspases mediate tumor necrosis factor-alpha-induced neutrophil apoptosis and downregulation of reactive oxygen production. Blood. 1999;93(2):674-85. PubMed PMID: 9885230.
  35. Hirata H, Takahashi A, Kobayashi S, Yonehara S, Sawai H, Okazaki T, Yamamoto K, Sasada M. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. The Journal of experimental medicine. 1998;187(4):587-600. PubMed PMID: 9463409; PMCID: 2212161.